Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 22, 2019
Distillery Therapeutics

Targeting NETs with DNASE1 in pneumococcal meningitis

BioCentury | Dec 13, 2017
Distillery Techniques

Disease models

BioCentury | Feb 10, 2017
Clinical News

Alidornase alfa: Interim Ph II data

BioCentury | Dec 30, 2016
Clinical News

AIR DNase: Completed Ph II enrollment

BioCentury | Nov 9, 2016
Distillery Therapeutics

Cancer

BioCentury | Jul 18, 2016
Clinical News

AIR DNase: Phase II started

BioCentury | Jun 16, 2016
Distillery Therapeutics

Therapeutics: Deoxyribonuclease I like 3 (DNASE1L3)

BioCentury | Aug 13, 2015
Translation in Brief

Guiding the way

Software tool predicts better CRISPR/Cas9 gene editing reagents
BioCentury | Apr 14, 2014
Clinical News

PulmoXen: Phase I data

Items per page:
1 - 9 of 9